Genome Editing to Abrogate Muscle Atrophy

Tingting Yang; Priyanka Gokulnath; Xinxiu Meng; Guoping Li; Junjie Xiao

doi:10.1007/978-981-19-5642-3_11

Genome Editing to Abrogate Muscle Atrophy

Adv Exp Med Biol. 2023:1396:157-176. doi: 10.1007/978-981-19-5642-3_11.

Authors

Tingting Yang^{1

2}, Priyanka Gokulnath³, Xinxiu Meng^{1

2}, Guoping Li³, Junjie Xiao⁴

Affiliations

¹ Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), School of Medicine, Shanghai University, Nantong, China.
² Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, China.
³ Cardiovascular Division of the Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
⁴ Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, China. junjiexiao@shu.edu.cn.

PMID: 36454466
DOI: 10.1007/978-981-19-5642-3_11

Abstract

Muscle atrophy is a multifactor syndrome, which not only decreases the patients' quality of life significantly but also increases the morbidity and mortality of patients with chronic diseases. At present, no effective clinical treatments for muscle atrophy except for exercise are available. The emerging field of genome editing is gaining momentum as it has shown great advantage in the treatment of various diseases, including muscle atrophy. In our current review, we systematically evaluate the etiology and related signaling pathways of muscle atrophy and discuss the application of genome editing in the treatment of muscle atrophy.

Keywords: Genome editing; Muscle atrophy; Treatment.

Publication types

Review

MeSH terms

Exercise
Gene Editing*
Humans
Motion
Muscular Atrophy / genetics
Muscular Atrophy / therapy
Quality of Life*